TY - JOUR
T1 - Comparative Analysis Revealed Circulating Methylation of PDGFRB Highly Related with Rheumatoid Arthritis Related Diseases
AU - Shan, Yu
AU - Guo, Mengru
AU - Liu, Jia
AU - Wang, Lei
AU - Shen, Yi
AU - Zhao, Jianan
AU - Wei, Kai
AU - Jiang, Ping
AU - Shi, Yiming
AU - Chang, Cen
AU - Zheng, Yixin
AU - Zhao, Fuyu
AU - Li, Yunshen
AU - Zhou, Mi
AU - Li, Chengzhen
AU - Guo, Shicheng
AU - Liang, Chao
AU - Qu, Huanru
AU - He, Dongyi
N1 - Funding information:
This work was funded by the National Natural Science Foundation of China [82074234, 82172386 and 81922081], State Administration of Traditional Chinese Medicine, Shanghai Municipal Health Commission, East China Region-based Chinese and Western Medicine Joint Disease Specialist Alliance, and Shanghai He Dongyi Famous Chinese Medicine Studio Construction Project [SHGZS-202220], Shanghai Municipal Health Commission [202340274], the Guangdong Basic and Applied Basic Research Foundation [2022A1515012164 to CL], and the Science, Technology and Innovation Commission of Shenzhen [JCYJ20210324104201005 to CL].
Publisher copyright:
© 2025 The Author(s). Published by Bentham Science Publishers.
PY - 2025/9/16
Y1 - 2025/9/16
N2 -
Introduction:To investigate the DNA methylation levels of platelet-derived growth factor receptor-
B [PDGFRB] cg25613180 across rheumatoid arthritis [RA] and various further rheumatic disorders,
including ankylosing spondylitis [AS], psoriatic arthritis [PsA], gouty arthritis, systemic lupus erythematosus
[SLE], sjögren’s syndrome [SS], and dermatomyositis [DM], using targeted DNA methylation
sequencing.
Methods:Methylation levels at PDGFRB cg25613180 were assessed in a cohort comprising RA patients,
healthy controls [HC], and individuals diagnosed with AS, PsA, gout, SLE, SS, and DM. Pearson-
’s correlation analysis was conducted to explore the relationship between PDGFRB cg25613180 methylation
levels and key clinical indices associated with RA. Additionally, both univariate and multivariate
logistic regression analyses were performed to evaluate the potential of methylation status as a diagnostic
biomarker for RA.
Results:Patients with RA demonstrated notably lower PDGFRB cg25613180 methylation levels than
the HCs, with similar trends noted in the SLE and DM teams. Methylation levels are negatively correlated
with inflammatory indicators like C-reactive protein [CRP], along with erythrocyte sedimentation
rate [ESR] in RA. Differences in haplotype methylation were also significant between the RA and other
groups, particularly for the CCCC and TCCC haplotypes. The logistic regression model provided high
discriminative accuracy between RA and other conditions, particularly AS.
Discussion:The results indicate that PDGFRB methylation, particularly at cg25613180, exhibits distinct
patterns in RA compared to other rheumatic diseases. This suggests its potential as a diagnostic biomarker
for RA. The negative correlation with inflammatory markers suggests a role for PDGFRB
methylation in the inflammatory processes underlying RA. The study also highlights the utility of haplotype-
specific methylation analysis in enhancing diagnostic accuracy.
Conclusion:This study identifies distinct PDGFRB methylation patterns in RA, supporting its potential
as a biomarker for diagnosis and differentiation from other rheumatic diseases. The findings open avenues
for further exploration of PDGFRB methylation in understanding the epigenetic landscape of autoimmune
rheumatic diseases and their potential for clinical applications.
AB -
Introduction:To investigate the DNA methylation levels of platelet-derived growth factor receptor-
B [PDGFRB] cg25613180 across rheumatoid arthritis [RA] and various further rheumatic disorders,
including ankylosing spondylitis [AS], psoriatic arthritis [PsA], gouty arthritis, systemic lupus erythematosus
[SLE], sjögren’s syndrome [SS], and dermatomyositis [DM], using targeted DNA methylation
sequencing.
Methods:Methylation levels at PDGFRB cg25613180 were assessed in a cohort comprising RA patients,
healthy controls [HC], and individuals diagnosed with AS, PsA, gout, SLE, SS, and DM. Pearson-
’s correlation analysis was conducted to explore the relationship between PDGFRB cg25613180 methylation
levels and key clinical indices associated with RA. Additionally, both univariate and multivariate
logistic regression analyses were performed to evaluate the potential of methylation status as a diagnostic
biomarker for RA.
Results:Patients with RA demonstrated notably lower PDGFRB cg25613180 methylation levels than
the HCs, with similar trends noted in the SLE and DM teams. Methylation levels are negatively correlated
with inflammatory indicators like C-reactive protein [CRP], along with erythrocyte sedimentation
rate [ESR] in RA. Differences in haplotype methylation were also significant between the RA and other
groups, particularly for the CCCC and TCCC haplotypes. The logistic regression model provided high
discriminative accuracy between RA and other conditions, particularly AS.
Discussion:The results indicate that PDGFRB methylation, particularly at cg25613180, exhibits distinct
patterns in RA compared to other rheumatic diseases. This suggests its potential as a diagnostic biomarker
for RA. The negative correlation with inflammatory markers suggests a role for PDGFRB
methylation in the inflammatory processes underlying RA. The study also highlights the utility of haplotype-
specific methylation analysis in enhancing diagnostic accuracy.
Conclusion:This study identifies distinct PDGFRB methylation patterns in RA, supporting its potential
as a biomarker for diagnosis and differentiation from other rheumatic diseases. The findings open avenues
for further exploration of PDGFRB methylation in understanding the epigenetic landscape of autoimmune
rheumatic diseases and their potential for clinical applications.
KW - PDGFRB
KW - rheumatoid arthritis
KW - DNA methylation
KW - biomarker
KW - targeted sequencing
KW - rheumatic diseases
U2 - 10.2174/0118715303377879250831134649
DO - 10.2174/0118715303377879250831134649
M3 - Journal article
SN - 1871-5303
JO - Endocrine, Metabolic and Immune Disorders - Drug Targets
JF - Endocrine, Metabolic and Immune Disorders - Drug Targets
M1 - e18715303377879
ER -
